References(39)
[1]
S. S. He,; J. C. Li,; Y. Lyu,; J. G. Huang,; K. Y. Pu, Near-infrared fluorescent macromolecular reporters for real-time imaging and urinalysis of cancer immunotherapy. J. Am. Chem. Soc. 2020, 142, 7075-7082.
[2]
R. S. Riley,; C. H. June,; R. Langer,; M. J. Mitchell, Delivery technologies for cancer immunotherapy. Nat. Rev. Drug. Dis. 2019, 18, 175-196.
[3]
J. C. Li,; D. Cui,; J. G. Huang,; S. S. He,; Z. B. Yang,; Y. Zhang,; Y. Luo,; K. Y. Pu, Organic semiconducting pro-nanostimulants for near-infrared photoactivatable cancer immunotherapy. Angew. Chem., Int. Ed. 2019, 58, 12680-12687.
[4]
N. N. Shao,; Y. X. Qi,; H. T. Lu,; D. Y. He,; B. Li,; Y. B. Huang, Photostability highly improved nanoparticles based on IR-780 and negative charged copolymer for enhanced photothermal therapy. ACS Biomater. Sci. Eng. 2019, 5, 795-804.
[5]
H. S. Jung,; P. Verwilst,; A. Sharma,; J. Shin,; J. L. Sessler,; J. S. Kim, Organic molecule-based photothermal agents: An expanding photothermal therapy universe. Chem. Soc. Rev. 2018, 47, 2280-2297.
[6]
H. Abrahamse,; M. R. Hamblin, New photosensitizers for photodynamic therapy. Biochem. J. 2016, 473, 347-364.
[7]
Y. Y. Jiang,; J. C. Li,; Z. L. Zeng,; C. Xie,; Y. Lyu,; K. Y. Pu, Organic photodynamic nanoinhibitor for synergistic cancer therapy. Angew. Chem., Int. Ed. 2019, 58, 8161-8165.
[8]
J. C. Li,; J. G. Huang,; Y. Lyu,; J. S. Huang,; Y. Y. Jiang,; C. Xie,; K. Y. Pu, Photoactivatable organic semiconducting pro-nanoenzymes. J. Am. Chem. Soc. 2019, 141, 4073-4079.
[9]
W. D. Ji,; B. Sun,; C. Q. Su, Targeting micrornas in cancer gene therapy. Genes. 2017, 8, 21.
[10]
Y. X. Qi,; H. H. Guo,; N. N. Hu,; D. Y. He,; S. Zhang,; Y. J. Chu,; Y. B. Huang,; X. Li,; L. L. Sun,; N. Y. Jin, Preclinical pharmacology and toxicology study of ad-htert-e1a-apoptin, a novel dual cancer- specific oncolytic adenovirus. Toxicol. Appl. Pharm. 2014, 280, 362-369.
[11]
G. W. Barendsen, Dose-survival curves of human cells in tissue culture irradiated with alpha-, beta-, 20-kV. X- and 200-kV. X-radiation. Nature 1962, 193, 1153-1155.
[12]
G. E. Laramore,; J. T. Griffith,; M. Boespflug,; J. G. Pelton,; T. Griffin,; B. R. Griffin,; K. J. Russell,; W. Koh,; R. G. Parker,; L. W. Davis, Fast neutron radiotherapy for sarcomas of soft tissue, bone, and cartilage. Am. J. Clin. Oncol. 1989, 12, 320-326.
[13]
R. J. Berry,; R. Oliver,; E. H. Porter, A fast-neutron source for radiotherapy. Nature. 1963, 199, 923.
[14]
R. L. Gragg,; R. M. Humphrey,; R. E. Meyn, The response of chinese hamster ovary cells to fast neutron radiotherapy beams: I. Relative biological effectiveness and oxygen enhancement ratio. Radiat. Res. 1976, 65, 71-82.
[15]
S. B. Curtis, An analysis of human kidney cell oxygen-enhancement ratios for fast-neutron beams and a prediction for negative pion beams. Radiat. Res. 1971, 46, 557-579.
[16]
H. M. Specht,; T. Neff,; W. Reuschel,; F. M. Wagner,; S. Kampfer,; J. J. Wilkens,; W. Petry,; S. E. Combs, Paving the road for modern particle therapy—What can we learn from the experience gained with fast neutron therapy in munich? Front. Oncol. 2015, 5, 262.
[17]
M. S. Sasaki,; S. Endo,; M. Hoshi,; T. Nomura, Neutron relative biological effectiveness in hiroshima and nagasaki atomic bomb survivors: A critical review. J. Radiat. Res. 2016, 57, 583-595.
[18]
K. Satoh,; H. Yasuda,; H. Kawakami,; S. Tashiro, Relative biological effectiveness of neutrons derived from the excess relative risk model with the atomic bomb survivors data managed by hiroshima university. Radiat. Prot. Dosim. 2018, 180, 346-350.
[19]
F. Hiraga,; T. Ooie, Synergistic effects of fast-neutron dose per epithermal neutron and 10B concentration on relative-biological- effectiveness dose for accelerator-based boron neutron capture therapy. Appl. Radiat. Isotopes 2019, 144, 1-4.
[20]
A. Zabihi,; J. Tello,; S. Incerti,; Z. Francis,; G. Forozani,; F. Semsarha,; A. Moslehi,; M. A. Bernal, Determination of fast neutron rbe using a fully mechanistic computational model. Appl. Radiat. Isotopes 2020, 156, 108952.
[21]
M. J. Luderer,; P. De La Puente,; A. K. Azab, Advancements in tumor targeting strategies for boron neutron capture therapy. Pharm. Res. 2015, 32, 2824-2836.
[22]
S. I. Masunaga,; K. Ono,; K. Akuta,; M. Akaboshi,; M. Abe,; K. Ando,; S. Koike, The radiosensitivity of quiescent cell populations in murine solid tumors in irradiation with fast neutrons. Int. J. Radiat. Oncol. 1994, 29, 239-242.
[23]
D. L. Schwartz,; J. Einck,; J. Bellon,; G. E. Laramore, Fast neutron radiotherapy for soft tissue and cartilaginous sarcomas at high risk for local recurrence. Int. J. Radiat. Oncol. 2001, 50, 449-456.
[24]
S. W. Jing,; H. H. Guo,; Y. X. Qi,; G. F. Yang,; Y. B. Huang, A portable fast neutron irradiation system for tumor therapy. Appl. Radiat. Isotopes 2020, 160, 109138.
[25]
S. Pavlides,; D. Whitaker-Menezes,; R. Castello-Cros,; N. Flomenberg,; A. K. Witkiewicz,; P. G. Frank,; M. C. Casimiro,; C. G. Wang,; P. Fortina,; S. Addya, The reverse warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009, 8, 3984-4001.
[26]
J. B. Spinelli,; H. Yoon,; A. E. Ringel,; S. Jeanfavre,; C. B. Clish,; M. C. Haigis, Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass. Science 2017, 358, 941-946.
[27]
E. H. Fang,; J. Q. Wang,; M. Hong,; L. D. Zheng,; Q. S. Tong, Valproic acid suppresses warburg effect and tumor progression in neuroblastoma. Biochem. Biophys. Res. Commun. 2019, 508, 9-16.
[28]
J. H. Hendry,; C. S. Potten,; C. Chadwick,; M. Bianchi, Cell death (apoptosis) in the mouse small intestine after low doses: Effects of dose-rate, 14.7 meV neutrons, and 600 meV (maximum energy) neutrons. Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med. 1982, 42, 611-620.
[29]
D. X. Liu,; S. Liu,; X. B. Jing,; X. Y. Li,; W. L. Li,; Y. B. Huang, Necrosis of cervical carcinoma by dichloroacetate released from electrospun polylactide mats. Biomaterials 2012, 33, 4362-4369.
[30]
D. X. Liu,; F. F. Wang,; J. Yue,; X. B. Jing,; Y. B. Huang, Metabolism targeting therapy of dichloroacetate-loaded electrospun mats on colorectal cancer. Drug. Deliv. 2015, 22, 136-143.
[31]
Z. Y. Zhang,; S. Liu,; Y. X. Qi,; D. F. Zhou,; Z. G. Xie,; X. B. Jing,; X. S. Chen,; Y. B. Huang, Time-programmed dca and oxaliplatin release by multilayered nanofiber mats in prevention of local cancer recurrence following surgery. J. Control. Release 2016, 235, 125-133.
[32]
A. H. W. Nias,; D. Greene,; M. Fox,; R. L. Thomas, Effect of 14 mev monoenergetic neutrons on hela and p388f cells in vitro. Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med. 1968, 13, 449-456.
[33]
C. Wu,; Q. Xu,; X. Y. Chen,; J. G. Liu, Delivery luteolin with folacin-modified nanoparticle for glioma therapy. Int. J. Nanomedicine 2019, 14, 7515-7531.
[34]
G. M. Grass,; S. A. Sweetana, In vitro measurement of gastrointestinal tissue permeability using a new diffusion cell. Pharm. Res. 1988, 5, 372-376.
[35]
S. Chen,; A. C. Cheng,; M. S. Wang,; X. Peng, Detection of apoptosis induced by new type gosling viral enteritis virus in vitro through fluorescein annexin v-fitc/pi double labeling. World. J. Gastroenterol. 2008, 14, 2174-2178.
[36]
V. Karthick,; S. Panda,; V. G. Kumar,; D. Kumar,; L. K. Shrestha,; K. Ariga,; K. Vasanth,; S. Chinnathambi,; T. S. Dhas,; K. S. U. Suganya, Quercetin loaded plga microspheres induce apoptosis in breast cancer cells. Appl. Surf. Sci. 2019, 487, 211-217.
[37]
M. Van Engeland,; L. J. M. Nieland,; F. C. S. Ramaekers,; B. Schutte,; C. P. M. Reutelingsperger, Annexin v-affinity assay: A review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry Part A 1998, 31, 1-9.
[38]
Z. Darzynkiewicz,; X. Li,; J. P. Gong, Assays of cell viability: Discrimination of cells dying by apoptosis. Method. Cell. Biol. 1994, 41, 15-38.
[39]
M. Sun,; D. P. Li,; X. Wang,; L. He,; X. D. Lv,; Y. Xu,; R. P. Tang, Intestine-penetrating, pH-sensitive and double-layered nanoparticles for oral delivery of doxorubicin with reduced toxicity. J. Mater. Chem. B 2019, 7, 3692-3703.